SHIKARI® Q-BEVA - (Bevacizumab, Avastin®)

SHIKARI Q-BEVA Instructions for Use PDF file

Enzyme immunoassay for the quantitative determination of Bevacizumab (Avastin®)..

The Matriks Biotek Shikari Q-BEVA Enzyme Immunoassay has been developed for the quantitative analysis of biologically active form of free bevacizumab (Avastin®)* in serum and plasma samples.

Serum through levels might be related to predict some clinical outcome during maintenance therapy. It was also possible that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. In this context, identification of biomarkers for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective minimum concentration in order to potentially avoid some side effects with a reliable method might be beneficial.

* Avastin® is a registered trademark of Genentech, Inc.

 

SHIKARI S-ATB Instructions for Use PDF file

Enzyme immunoassay for the qualitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma.



The Matriks Biotek Antibody to Bevacizumab (Avastin®)* Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma. It is for research use only.

As with all therapeutic proteins, there is a potential for immunogenicity. Accoring to the manufacturer’s product insert; the incidence of antibody development in patients receiving Avastin has not been adequately determined because the assay sensitivity was inadequate to reliably detect lower titers. Enzyme-linked immunosorbent assays (ELISAs) were performed on sera from approximately 500 patients treated with Avastin, primarily in combination with chemotherapy. High titer human anti-Avastin antibodies were not detected. Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Avastin with the incidence of antibodies to other products may be misleading.

The Matriks Biotek Antibody to Bevacizumab ELISA Kit can be used for monitoring anti-Bevacizumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures.

* Avastin® is a registered trademark of Genentech, Inc.

 

	Q-BEVA	S-ATB
	Free Bevacizumab (Avastin®) quantitative analyses	Bevacizumab (Avastin®) antibodies  qualitative  analyses
Required Volume ( µl)	5	25
Total Time (min)	170	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Dedection Limit ( ng/mL)	30	+/-
Spike Recovery (%)	99	-
Shelf Life (year)	1	1